北京陽光諾和藥物研究股份有限公司是科創板上市企業（688621），是專注于仿制和創新藥物研究，致力于以技術服務為核心，推動中國醫藥行業發展，為客戶提供「臨床前＋臨床+CDMO」全過程藥物研發服務的綜合型CRO公司。陽光諾和從藥物發現、到藥理藥效、藥學研究，再到臨床研究資源的整合，生物樣本檢測團隊的構建，生產制造能力的整合，成功打造了全過程CRO服務模式。

Beijing Sun-novo Pharmaceutical Research Co., Ltd. is a listed company on the Science and Technology Innovation Board (688621). Focusing on generic and innovative drug research, it is a comprehensive CRO company committed to providing technological services, endeavoring to promote China’s pharmaceutical industry. From drug discovery, pharmacological and pharmaceutical research, to the integration of clinical research resources, biological sample testing and manufacturing capabilities, Sun-novo delivers "preclinical+clinical+CDMO" drug R&D services and a whole-process CRO model.

公司主營業務涵蓋藥理藥效、臨床研究、CDMO、創新藥開發、仿制藥開發及一致性評價的綜合研發服務，服務內容主要包括藥物發現、藥理藥效、藥學研究、臨床研究和生物分析。可進行完整的化學藥研發、仿制藥一致性評價、藥物代謝分析與評價研究、多肽藥物研發、臨床生物等效性試驗、藥物Ⅰ-Ⅳ期臨床研究、生物樣品檢測、注冊申報（國內和進口）、國際合作等服務。

As a one-stop-shop with integrated services and technologies, Sun-novo serves from drug discovery, potency testing, biological analysis, clinical research, to CDMO, innovative drug development, generic drug development and consistency evaluation. It’s also equipped with strong expertise to conduct whole-process chemical drug and peptide drug R&D, generic drug consistency evaluation, metabolism analysis, clinical bioequivalence trials, phase I-IV clinical studies, biological sample testing, as well as drug registration and application (domestic and imported) for international cooperation.